Pharmacokinetic consequences of pegylation.
Pegylation, generally described as the molecular attachment of polyethylene glycols (PEGs) with different molecular weights to active drug molecules or surface treatment of drug-bearing particles with PEGs, is one of the most promising and extensively studied strategies with the goal of improving the pharmacokinetic behavior of the therapeutic drugs. A variety of PEGs, both linear and branched, with different molecular weights have been exploited successfully for use in this procedure in the form of reactive PEG species. Both reversible and irreversible PEG-drug conjugates have been prepared with relative advantages/disadvantages. The main pharmacokinetic outcomes of pegylation are summarized as changes occurring in overall circulation life-span, tissue distribution pattern, and elimination pathway of the parent drug/particle. Based on these favorable pharmacokinetic consequences leading to desired pharmacodynamic outcomes, a variety of proteins/peptides as well as small molecule drugs have been pegylated and evaluated successfully. Also a number of corresponding products have been approved by the U.S. FDA for specific clinical indications and some others are underway. In this article, the chemistry, rationale, strategies, pharmacokinetic outcomes, and therapeutic possibilities of pegylated drugs are reviewed with pharmacokinetic aspects presented with more details.
Hamidi
Mehrdad
M
Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. hamidim@sums.ac.ir
Azadi
Amir
A
Rafiei
Pedram
P
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D006801:Humans; D010455:Peptides / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D010455:Peptides; D004364:Pharmaceutical Preparations; D011092:Polyethylene Glycols